- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT02353897
Patient and Physician's Satisfaction After a Long Term Treatment of Glabellar Lines With Dysport® (APPEAL)
4. november 2020 opdateret af: Ipsen
An Assessment of Patient and Physician's Satisfaction After a Long Term Treatment of Glabellar Lines With Dysport®.
This study aims to look at patient and physician satisfaction of long term Glabellar lines (GL) treatment with Dysport in a real life setting.
It will also allow better understanding of what patients expect from the treatment, and the injection practices used by doctors.
Studieoversigt
Status
Afsluttet
Betingelser
Undersøgelsestype
Observationel
Tilmelding (Faktiske)
150
Kontakter og lokationer
Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.
Studiesteder
-
-
-
Malvern, Australien, 3144
- ERASE
-
Sydney, Australien, 2217
- SouthDerm
-
-
-
-
-
Botucatu, Brasilien, 18603-390
- Clinica Laura Bariquelo Buratini
-
-
-
-
-
Moscow, Den Russiske Føderation, 105062
- Centre of Aesthetic Medicine "Chistie prudi"
-
Moscow, Den Russiske Føderation, 117630
- Preventive Medicine Clinic "Vallex M"
-
Moscow, Den Russiske Føderation, 119002
- Plastic Surgery Institute
-
Novosibirsk, Den Russiske Føderation, 630071
- FI IF & TC & apos; Eye microsurgery & apos
-
St Petersburg, Den Russiske Føderation, 197110
- Clinic of Aesthetic Medicine
-
-
-
-
-
Kocaeli, Kalkun, 41380
- Kocaeli University School of Medecine Umuttepe
-
-
-
-
-
Almaty, Kasakhstan, 050022
- Laser Center DARUS
-
-
-
-
-
Beirut, Libanon, 70920
- Dr Haddad Clinics
-
-
-
-
-
Brno, Tjekkiet, 60200
- Estetická Dermatologie
-
Praha, Tjekkiet, 14000
- BcD Clinic s.r.o.
-
-
-
-
-
Kyiv, Ukraine, 03087
- Clinic of Aesthetic medicine "Ankor"
-
-
Deltagelseskriterier
Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.
Berettigelseskriterier
Aldre berettiget til at studere
18 år og ældre (Voksen, Ældre voksen)
Tager imod sunde frivillige
Ingen
Køn, der er berettiget til at studere
Alle
Prøveudtagningsmetode
Ikke-sandsynlighedsprøve
Studiebefolkning
Private practices and clinics
Beskrivelse
Inclusion Criteria:
- Adult patient with moderate to severe GL naïve of any type of aesthetic treatment/procedure (invasive and non-invasive) for GL who provided written informed consent to take part.
- Patient who has prior to and independent of the study decided to undergo long term treatment of GL only (at least three cycles).
- Patient able to comply with the protocol (completion of web questionnaires).
- Patient whom physician intended to treat with Dysport independent of participation in the study.
Exclusion Criteria:
- Patient already included in this study.
- Participation in an interventional trial within 30 days prior to study entry.
- Patient who is at risk in terms of precautions, warnings, and contraindication (follow local Summary of Product Characteristics (SmPC) of Dysport).
- Female patient who is pregnant, nursing or planning a pregnancy during the study.
- Hypersensitivity to Dysport® or to its excipients.
- Presence of infection at the proposed injection sites.
- Presence of myasthenia gravis, Eaton Lambert syndrome or amyotrophic lateral sclerosis.
Studieplan
Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
To assess patient satisfaction regarding GL after three injection cycles of Dysport.
Tidsramme: Within 3 weeks ±7 days of visit 3
|
Assessed by patient auto questionnaire completion
|
Within 3 weeks ±7 days of visit 3
|
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
To describe patient individual expectations.
Tidsramme: Within 3 weeks ±7 days of visit 1 and 2
|
Assessed by patient auto questionnaire completion
|
Within 3 weeks ±7 days of visit 1 and 2
|
|
To assess patient satisfaction after one and two injection cycles of Dysport.
Tidsramme: Within 3 weeks ±7 days of visit 1 and 2
|
Assessed by patient auto questionnaire completion
|
Within 3 weeks ±7 days of visit 1 and 2
|
|
To describe factors associated with patient satisfaction such as attractiveness, self-esteem, self-perceived age, desire to receive another injection.
Tidsramme: Within 3 weeks ±7 days of visit 1 and 2
|
Assessed by patient auto questionnaire completion
|
Within 3 weeks ±7 days of visit 1 and 2
|
|
To assess the GL severity (at rest and maximum frown) as per usual practice.
Tidsramme: Baseline (visit 1) and visit 3
|
Physician assessment using GL severity scale
|
Baseline (visit 1) and visit 3
|
|
To assess physician satisfaction after one and three injection cycles of Dysport.
Tidsramme: Visit 1 follow up visit and visit 3 follow up visit (if performed)
|
5 point Likert scale
|
Visit 1 follow up visit and visit 3 follow up visit (if performed)
|
|
To describe Dysport injection practices: muscles injected, total injected units, total volume injected, number of injection points and interval between injections.
Tidsramme: From visit 1 until the end of the study
|
From visit 1 until the end of the study
|
Samarbejdspartnere og efterforskere
Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.
Sponsor
Publikationer og nyttige links
Den person, der er ansvarlig for at indtaste oplysninger om undersøgelsen, leverer frivilligt disse publikationer. Disse kan handle om alt relateret til undersøgelsen.
Datoer for undersøgelser
Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.
Studer store datoer
Studiestart
1. oktober 2014
Primær færdiggørelse (Faktiske)
1. juli 2016
Studieafslutning (Faktiske)
1. juli 2016
Datoer for studieregistrering
Først indsendt
29. januar 2015
Først indsendt, der opfyldte QC-kriterier
29. januar 2015
Først opslået (Skøn)
3. februar 2015
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
5. november 2020
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
4. november 2020
Sidst verificeret
1. november 2020
Mere information
Begreber relateret til denne undersøgelse
Andre undersøgelses-id-numre
- Y-79-52120-201
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .
Kliniske forsøg med Glabellar linjer
-
Espad PharmedCenter for Research and Training in Skin Diseases and LeprosyAfsluttetGlabellar pandelinjer | Glabellar linjerIran, Islamisk Republik
-
Eirion Therapeutics Inc.Aktiv, ikke rekrutterendeGlabellar linjerForenede Stater
-
AllerganAfsluttet
-
Galderma R&DAfsluttet
-
AbbVieAfsluttetGlabellar linjerKina, Japan, Taiwan
-
Protox Inc.AfsluttetGlabellar pandelinjerKorea, Republikken
-
AbbVieAfsluttetGlabellar linjerForenede Stater, Canada, Tyskland, Ungarn, Polen
-
Protox Inc.AfsluttetGlabellar pandelinjerKorea, Republikken
-
AllerganAfsluttetGlabellar linjerForenede Stater